Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 44 entries
Sorted by: Best Match Show Resources per page
Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia.

Clinical investigation

Devidas M, Anderson JR.
PMID: 24273641
Clin Investig (Lond). 2013 Sep;3(9). doi: 10.4155/cli.13.71.

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Although outcomes for children with ALL have improved dramatically over the last 50 years, ALL remains the leading cause of childhood cancer death. In addition, high-risk patient subsets can...

Cite
Devidas M, Anderson JR. Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia. Clin Investig (Lond). 2013;3(9)doi: 10.4155/cli.13.71.
Devidas, M., & Anderson, J. R. (2013). Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia. Clinical investigation, 3(9), . https://doi.org/10.4155/cli.13.71
Devidas, Meenakshi, and Anderson, James R. "Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia." Clinical investigation vol. 3,9 (2013). doi: https://doi.org/10.4155/cli.13.71
Devidas M, Anderson JR. Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia. Clin Investig (Lond). 2013 Sep;3(9). doi: 10.4155/cli.13.71. PMID: 24273641; PMCID: PMC3834963.
Copy Download .nbib Format: NLM
Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group.

The journal of pathology. Clinical research

Volchenboum SL, Andrade J, Huang L, Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U, Triche TJ, Lawlor ER.
PMID: 26052443
J Pathol Clin Res. 2015 Apr;1(2):83-94. doi: 10.1002/cjp2.9.

Relapse of Ewing sarcoma (ES) can occur months or years after initial remission and salvage therapy for relapsed disease is usually ineffective. Thus, there is great need to develop biomarkers that can predict which patients are at risk for...

Cite
Volchenboum SL, Andrade J, Huang L, et al. Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group. J Pathol Clin Res. 2015;1(2):83-94doi: 10.1002/cjp2.9.
Volchenboum, S. L., Andrade, J., Huang, L., Barkauskas, D. A., Krailo, M., Womer, R. B., Ranft, A., Potratz, J., Dirksen, U., Triche, T. J., & Lawlor, E. R. (2015). Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group. The journal of pathology. Clinical research, 1(2), 83-94. https://doi.org/10.1002/cjp2.9
Volchenboum, Samuel L, et al. "Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group." The journal of pathology. Clinical research vol. 1,2 (2015): 83-94. doi: https://doi.org/10.1002/cjp2.9
Volchenboum SL, Andrade J, Huang L, Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U, Triche TJ, Lawlor ER. Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group. J Pathol Clin Res. 2015 Apr;1(2):83-94. doi: 10.1002/cjp2.9. PMID: 26052443; PMCID: PMC4457396.
Copy Download .nbib Format: NLM
Children's Oncology Group's 2013 blueprint for research: epidemiology.

Pediatric blood & cancer

Spector LG, Ross JA, Olshan AF.
PMID: 23255344
Pediatr Blood Cancer. 2013 Jun;60(6):1059-62. doi: 10.1002/pbc.24434. Epub 2012 Dec 19.

Investigators worldwide have for over 40 years conducted case-control studies aimed at determining the causes of childhood cancer. The central challenge to conducting such research is the rarity of childhood cancer, thus many studies aggregate cases through clinical trials...

Cite
Spector LG, Ross JA, Olshan AF. Children's Oncology Group's 2013 blueprint for research: epidemiology. Pediatr Blood Cancer. 2012;60(6):1059-62doi: 10.1002/pbc.24434.
Spector, L. G., Ross, J. A., Olshan, A. F. (2013). Children's Oncology Group's 2013 blueprint for research: epidemiology. Pediatric blood & cancer, 60(6), 1059-62. https://doi.org/10.1002/pbc.24434
Spector, Logan G, et al. "Children's Oncology Group's 2013 blueprint for research: epidemiology." Pediatric blood & cancer vol. 60,6 (2013): 1059-62. doi: https://doi.org/10.1002/pbc.24434
Spector LG, Ross JA, Olshan AF. Children's Oncology Group's 2013 blueprint for research: epidemiology. Pediatr Blood Cancer. 2013 Jun;60(6):1059-62. doi: 10.1002/pbc.24434. Epub 2012 Dec 19. PMID: 23255344; PMCID: PMC3726183.
Copy Download .nbib Format: NLM
Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Frontiers in oncology

Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER.
PMID: 23761859
Front Oncol. 2013 Jun 06;3:141. doi: 10.3389/fonc.2013.00141. eCollection 2013.

A goal of the COG Ewing Sarcoma (ES) Biology Committee is enabling identification of reliable biomarkers that can predict treatment response and outcome through the use of prospectively collected tissues and correlative studies in concert with COG therapeutic studies....

Cite
Shukla N, Schiffman J, Reed D, et al. Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Front Oncol. 2013;3:141doi: 10.3389/fonc.2013.00141.
Shukla, N., Schiffman, J., Reed, D., Davis, I. J., Womer, R. B., Lessnick, S. L., Lawlor, E. R. (2013). Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Frontiers in oncology, 3141. https://doi.org/10.3389/fonc.2013.00141
Shukla, Neerav, et al. "Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group." Frontiers in oncology vol. 3 (2013): 141. doi: https://doi.org/10.3389/fonc.2013.00141
Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER. Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Front Oncol. 2013 Jun 06;3:141. doi: 10.3389/fonc.2013.00141. eCollection 2013. PMID: 23761859; PMCID: PMC3674398.
Copy Download .nbib Format: NLM
Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.

Nature medicine

Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S.
PMID: 30705421
Nat Med. 2019 Mar;25(3):530. doi: 10.1038/s41591-019-0369-7.

In the version of this article originally published, the color key in Fig. 1a was wrong. In the Cytogenetics key, the box over t(8;21) originally was green. It should have been red, matching the color of the sections of...

Cite
Bolouri H, Farrar JE, Triche T, et al. Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2019;25(3):530doi: 10.1038/s41591-019-0369-7.
Bolouri, H., Farrar, J. E., Triche, T., Ries, R. E., Lim, E. L., Alonzo, T. A., Ma, Y., Moore, R., Mungall, A. J., Marra, M. A., Zhang, J., Ma, X., Liu, Y., Liu, Y., Auvil, J. M. G., Davidsen, T. M., Gesuwan, P., Hermida, L. C., Salhia, B., Capone, S., Ramsingh, G., Zwaan, C. M., Noort, S., Piccolo, S. R., Kolb, E. A., Gamis, A. S., Smith, M. A., Gerhard, D. S., & Meshinchi, S. (2019). Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature medicine, 25(3), 530. https://doi.org/10.1038/s41591-019-0369-7
Bolouri, Hamid, et al. "Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions." Nature medicine vol. 25,3 (2019): 530. doi: https://doi.org/10.1038/s41591-019-0369-7
Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S. Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2019 Mar;25(3):530. doi: 10.1038/s41591-019-0369-7. PMID: 30705421; PMCID: PMC7747938.
Copy Download .nbib Format: NLM
Reply to I.J. Cohen.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Hardy KK, Embry LM, Kairalla JA, Helian S, Devidas M, Armstrong FD, Hunger S, Carroll WL, Larsen E, Raetz EA, Loh ML, Yang W, Relling MV, Noll RB, Winick N.
PMID: 29045162
J Clin Oncol. 2017 Dec 10;35(35):3989-3991. doi: 10.1200/JCO.2017.75.7252. Epub 2017 Oct 18.

No abstract available.

Cite
Hardy KK, Embry LM, Kairalla JA, et al. Reply to I.J. Cohen. J Clin Oncol. 2017;35(35):3989-3991doi: 10.1200/JCO.2017.75.7252.
Hardy, K. K., Embry, L. M., Kairalla, J. A., Helian, S., Devidas, M., Armstrong, F. D., Hunger, S., Carroll, W. L., Larsen, E., Raetz, E. A., Loh, M. L., Yang, W., Relling, M. V., Noll, R. B., & Winick, N. (2017). Reply to I.J. Cohen. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(35), 3989-3991. https://doi.org/10.1200/JCO.2017.75.7252
Hardy, Kristina K, et al. "Reply to I.J. Cohen." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 35,35 (2017): 3989-3991. doi: https://doi.org/10.1200/JCO.2017.75.7252
Hardy KK, Embry LM, Kairalla JA, Helian S, Devidas M, Armstrong FD, Hunger S, Carroll WL, Larsen E, Raetz EA, Loh ML, Yang W, Relling MV, Noll RB, Winick N. Reply to I.J. Cohen. J Clin Oncol. 2017 Dec 10;35(35):3989-3991. doi: 10.1200/JCO.2017.75.7252. Epub 2017 Oct 18. PMID: 29045162.
Copy Download .nbib Format: NLM
AACR Cancer Progress Report 2014.

Clinical cancer research : an official journal of the American Association for Cancer Research

Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ.
PMID: 25228531
Clin Cancer Res. 2014 Oct 01;20(19):S1-S112. doi: 10.1158/1078-0432.CCR-14-2123. Epub 2014 Sep 16.

No abstract available.

Cite
Arteaga CL, Adamson PC, Engelman JA, et al. AACR Cancer Progress Report 2014. Clin Cancer Res. 2014;20(19):S1-S112doi: 10.1158/1078-0432.CCR-14-2123.
Arteaga, C. L., Adamson, P. C., Engelman, J. A., Foti, M., Gaynor, R. B., Hilsenbeck, S. G., Limburg, P. J., Lowe, S. W., Mardis, E. R., Ramsey, S., Rebbeck, T. R., Richardson, A. L., Rubin, E. H., & Weiner, G. J. (2014). AACR Cancer Progress Report 2014. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(19), S1-S112. https://doi.org/10.1158/1078-0432.CCR-14-2123
Arteaga, Carlos L, et al. "AACR Cancer Progress Report 2014." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 20,19 (2014): S1-S112. doi: https://doi.org/10.1158/1078-0432.CCR-14-2123
Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ. AACR Cancer Progress Report 2014. Clin Cancer Res. 2014 Oct 01;20(19):S1-S112. doi: 10.1158/1078-0432.CCR-14-2123. Epub 2014 Sep 16. PMID: 25228531; PMCID: PMC4666597.
Copy Download .nbib Format: NLM
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA, Mascarenhas L.
PMID: 34652968
J Clin Oncol. 2021 Dec 20;39(36):4029-4038. doi: 10.1200/JCO.21.00358. Epub 2021 Oct 15.

PURPOSE: The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed chemotherapy improved survival outcomes for patients with previously untreated nonmetastatic Ewing sarcoma.METHODS: Patients were...

Cite
Leavey PJ, Laack NN, Krailo MD, et al. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021;39(36):4029-4038doi: 10.1200/JCO.21.00358.
Leavey, P. J., Laack, N. N., Krailo, M. D., Buxton, A., Randall, R. L., DuBois, S. G., Reed, D. R., Grier, H. E., Hawkins, D. S., Pawel, B., Nadel, H., Womer, R. B., Letson, G. D., Bernstein, M., Brown, K., Maciej, A., Chuba, P., Ahmed, A. A., Indelicato, D. J., Wang, D., Marina, N., Gorlick, R., Janeway, K. A., & Mascarenhas, L. (2021). Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(36), 4029-4038. https://doi.org/10.1200/JCO.21.00358
Leavey, Patrick J, et al. "Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,36 (2021): 4029-4038. doi: https://doi.org/10.1200/JCO.21.00358
Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA, Mascarenhas L. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021 Dec 20;39(36):4029-4038. doi: 10.1200/JCO.21.00358. Epub 2021 Oct 15. PMID: 34652968; PMCID: PMC8677904.
Copy Download .nbib Format: NLM
Variations in mRNA and protein levels of Ikaros family members in pediatric T cell acute lymphoblastic leukemia.

Annals of translational medicine

Mitchell JL, Yankee TM.
PMID: 27826566
Ann Transl Med. 2016 Oct;4(19):363. doi: 10.21037/atm.2016.09.29.

BACKGROUND: Pediatric T cell acute lymphoblastic leukemia (T-ALL) is a highly heterogeneous disease in which the cells share phenotypic characteristics with normal human thymocytes. The Ikaros family of transcription factors includes five members that are required for normal T...

Cite
Mitchell JL, Yankee TM. Variations in mRNA and protein levels of Ikaros family members in pediatric T cell acute lymphoblastic leukemia. Ann Transl Med. 2016;4(19):363doi: 10.21037/atm.2016.09.29.
Mitchell, J. L., & Yankee, T. M. (2016). Variations in mRNA and protein levels of Ikaros family members in pediatric T cell acute lymphoblastic leukemia. Annals of translational medicine, 4(19), 363. https://doi.org/10.21037/atm.2016.09.29
Mitchell, Julie L, and Yankee, Thomas M. "Variations in mRNA and protein levels of Ikaros family members in pediatric T cell acute lymphoblastic leukemia." Annals of translational medicine vol. 4,19 (2016): 363. doi: https://doi.org/10.21037/atm.2016.09.29
Mitchell JL, Yankee TM. Variations in mRNA and protein levels of Ikaros family members in pediatric T cell acute lymphoblastic leukemia. Ann Transl Med. 2016 Oct;4(19):363. doi: 10.21037/atm.2016.09.29. PMID: 27826566; PMCID: PMC5075847.
Copy Download .nbib Format: NLM
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

Clinical cancer research : an official journal of the American Association for Cancer Research

Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM.
PMID: 33504555
Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. doi: 10.1158/1078-0432.CCR-20-3909. Epub 2021 Jan 27.

PURPOSE: Previously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children with high-risk neuroblastoma that had responded to induction and consolidation therapy. These results served as the...

Cite
Yu AL, Gilman AL, Ozkaynak MF, et al. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021;27(8):2179-2189doi: 10.1158/1078-0432.CCR-20-3909.
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., Naranjo, A., Diccianni, M. B., Gan, J., Hank, J. A., Batova, A., London, W. B., Tenney, S. C., Smith, M., Shulkin, B. L., Parisi, M., Matthay, K. K., Cohn, S. L., Maris, J. M., Bagatell, R., Park, J. R., & Sondel, P. M. (2021). Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(8), 2179-2189. https://doi.org/10.1158/1078-0432.CCR-20-3909
Yu, Alice L, et al. "Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,8 (2021): 2179-2189. doi: https://doi.org/10.1158/1078-0432.CCR-20-3909
Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. doi: 10.1158/1078-0432.CCR-20-3909. Epub 2021 Jan 27. PMID: 33504555; PMCID: PMC8046731.
Copy Download .nbib Format: NLM
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia.

Nature cancer

Oshima K, Zhao J, Pérez-Durán P, Brown JA, Patiño-Galindo JA, Chu T, Quinn A, Gunning T, Belver L, Ambesi-Impiombato A, Tosello V, Wang Z, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Balbin M, Nicolas C, Gastier-Foster JM, Devidas M, Loh ML, Paietta E, Tallman MS, Rowe JM, Litzow M, Minden MD, Meijerink J, Rabadan R, Ferrando A.
PMID: 33796864
Nat Cancer. 2020 Nov;1(11):1113-1127. doi: 10.1038/s43018-020-00124-1. Epub 2020 Oct 19.

Multi-agent combination chemotherapy can be curative in acute lymphoblastic leukemia (ALL). Still, patients with primary refractory disease or with relapsed leukemia have a very poor prognosis. Here we integrate an in-depth dissection of the mutational landscape across diagnostic and...

Cite
Oshima K, Zhao J, Pérez-Durán P, et al. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nat Cancer. 2020;1(11):1113-1127doi: 10.1038/s43018-020-00124-1.
Oshima, K., Zhao, J., Pérez-Durán, P., Brown, J. A., Patiño-Galindo, J. A., Chu, T., Quinn, A., Gunning, T., Belver, L., Ambesi-Impiombato, A., Tosello, V., Wang, Z., Sulis, M. L., Kato, M., Koh, K., Paganin, M., Basso, G., Balbin, M., Nicolas, C., Gastier-Foster, J. M., Devidas, M., Loh, M. L., Paietta, E., Tallman, M. S., Rowe, J. M., Litzow, M., Minden, M. D., Meijerink, J., Rabadan, R., & Ferrando, A. (2020). Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nature cancer, 1(11), 1113-1127. https://doi.org/10.1038/s43018-020-00124-1
Oshima, Koichi, et al. "Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia." Nature cancer vol. 1,11 (2020): 1113-1127. doi: https://doi.org/10.1038/s43018-020-00124-1
Oshima K, Zhao J, Pérez-Durán P, Brown JA, Patiño-Galindo JA, Chu T, Quinn A, Gunning T, Belver L, Ambesi-Impiombato A, Tosello V, Wang Z, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Balbin M, Nicolas C, Gastier-Foster JM, Devidas M, Loh ML, Paietta E, Tallman MS, Rowe JM, Litzow M, Minden MD, Meijerink J, Rabadan R, Ferrando A. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nat Cancer. 2020 Nov;1(11):1113-1127. doi: 10.1038/s43018-020-00124-1. Epub 2020 Oct 19. PMID: 33796864; PMCID: PMC8011577.
Copy Download .nbib Format: NLM
MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.

Oncotarget

Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H.
PMID: 29464082
Oncotarget. 2017 Dec 15;9(5):6416-6432. doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19.

Neuroblastomas with a high mitosis-karyorrhexis index (High-MKI) are often associated with

Cite
Niemas-Teshiba R, Matsuno R, Wang LL, et al. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget. 2017;9(5):6416-6432doi: 10.18632/oncotarget.23740.
Niemas-Teshiba, R., Matsuno, R., Wang, L. L., Tang, X. X., Chiu, B., Zeki, J., Coburn, J., Ornell, K., Naranjo, A., Van Ryn, C., London, W. B., Hogarty, M. D., Gastier-Foster, J. M., Look, A. T., Park, J. R., Maris, J. M., Cohn, S. L., Seeger, R. C., Asgharzadeh, S., Ikegaki, N., & Shimada, H. (2018). MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget, 9(5), 6416-6432. https://doi.org/10.18632/oncotarget.23740
Niemas-Teshiba, Risa, et al. "MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group." Oncotarget vol. 9,5 (2018): 6416-6432. doi: https://doi.org/10.18632/oncotarget.23740
Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget. 2017 Dec 15;9(5):6416-6432. doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19. PMID: 29464082; PMCID: PMC5814222.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 44 entries